Hyperthermia Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device Type (Microwave Hyperthermia Device, Ultrasound Hyperthermia Device, Infrared Hyperthermia Device, Short-wave Hyperthermia Device), By Application (Prostate Cancer, Breast Cancer, Cervical Cancer, Skin Cancer, Other Cancers), By End User (Hospitals & Clinics, Specialty Centers
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationHyperthermia Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device Type (Microwave Hyperthermia Device, Ultrasound Hyperthermia Device, Infrared Hyperthermia Device, Short-wave Hyperthermia Device), By Application (Prostate Cancer, Breast Cancer, Cervical Cancer, Skin Cancer, Other Cancers), By End User (Hospitals & Clinics, Specialty Centers
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 151.26 Million |
| CAGR (2024-2029) | 5.62% |
| Fastest Growing Segment | Breast Cancer |
| Largest Market | North America |
| Market Size (2029) | USD 207.63 Million |
Market Overview
Global Hyperthermia Cancer Treatment Market was valued at USD 151.26 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.62% through 2029.
Hyperthermia treatments are administered using various methods, including external or internal heating devices, microwave applicators, or warm water blankets. Despite being a relatively small segment of the oncology market currently, hyperthermia is gaining traction as technological advancements improve treatment precision and effectiveness. However, widespread awareness among patients and healthcare providers about hyperthermia as a viable treatment option remains limited.
Integrating hyperthermia with chemotherapy, radiation therapy, and surgical procedures presents logistical challenges but holds promise in enhancing overall treatment outcomes. As awareness grows and technological integration advances, hyperthermia is expected to play a more prominent role in global cancer treatment strategies, offering new avenues of hope in the battle against cancer.
Key Market Drivers
Increasing Cancer Incidence
The rising incidence of cancer globally has created a larger population in need of effective treatment options. Hyperthermia offers an alternative or supplementary approach to traditional therapies such as chemotherapy and radiation, particularly beneficial for cancers that are resistant to standard treatments. According to a report from WHO, approximately 1 in 5 people develop cancer during their lifetime, with 1 in 9 men and 1 in 12 women succumbing to the disease. Disparities based on the Human Development Index (HDI) indicate that countries with higher HDI levels are projected to experience a significant increase in new cases by 2050 compared to countries with lower HDI levels.
There is a growing demand for innovative therapies like hyperthermia driven by the need to improve treatment efficacy and enhance patient outcomes. Hyperthermia equips healthcare providers with additional tools to combat cancer, especially in cases where traditional therapies have limited effectiveness, thereby expanding the range of treatment options found at to clinicians and patients. Clinical studies and trials have demonstrated that combining hyperthermia with other treatments can boost therapeutic effectiveness and potentially improve survival rates, making it an attractive choice for managing various types of cancers.
Regulatory bodies are increasingly recognizing hyperthermia as a safe and effective treatment option when used in conjunction with standard therapies. This recognition facilitates easier adoption and integration of hyperthermia into clinical practice. The growing global incidence of cancer underscores the critical need for effective treatments, driving the expansion of the hyperthermia cancer treatment market by broadening its applicability and acceptance within oncology practices.
Growing Research and Development
Increased research and development efforts lead to advancements in hyperthermia treatment technologies and techniques, resulting in the creation of more effective and precise devices for heating tumors or specific tissues, thereby enhancing treatment outcomes. A team of researchers from China has developed adjuvant biomaterials to enhance Microwave Ablation (MWA), which holds practical significance. Their work demonstrates that alginate-based hydrogels with high Ca2+ concentration improve heating efficiency and limit the heating zone under microwave exposure. This approach synergizes with mild hyperthermia to induce immunogenic cell death by disrupting intracellular Ca2+ balance. The combination of Ca2+-surplus alginate hydrogel with MWA effectively ablates various tumors in animal models using reduced power levels. This study underscores the potential of metallo-alginate hydrogel as a microwave-responsive and immunostimulatory biomaterial to augment MWA therapy, showing promise for clinical application.
Research and development also facilitate exploring new applications and combinations of hyperthermia with therapies like chemotherapy, radiation therapy, and immunotherapy. This expands the scope of hyperthermia across different cancer types and stages. For instance, in 2024, Amrita Hospital in Faridabad, India, announced a government-funded initiative to develop a robot-assisted ultrasound system for image-guided therapies and hyperthermia in cancer treatment, led by the head of their Radiation Oncology department.
Continued research validates the efficacy and safety of hyperthermia, crucial for obtaining regulatory approvals and increasing acceptance among healthcare providers. For example, a 2024 study published in Nature demonstrated that inhibiting heat shock factor 1 enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model, highlighting ongoing advancements. The focus on research and development in hyperthermia cancer treatment drives technological progress and expands the market by addressing unmet medical needs and improving outcomes for cancer patients worldwide.
Key Market Challenges
Cost and Reimbursement Issues
Implementing hyperthermia treatment necessitates specialized equipment like electromagnetic or ultrasound devices capable of heating tumors to therapeutic temperatures, which are costly to acquire and maintain, necessitating substantial initial investment for healthcare facilities. Alongside equipment costs, there are ongoing operational expenses including regular maintenance, calibration, and the requirement for trained personnel to effectively operate and oversee treatment sessions. Each hyperthermia session contributes to the overall expense of cancer care, which can be considerable, particularly when combined with conventional treatments such as radiation therapy or chemotherapy. Patients undergoing multiple sessions may face significant cumulative financial burdens.
Securing adequate reimbursement for hyperthermia treatments from healthcare payers, such as insurance companies or government health programs, poses challenges. Reimbursement rates often fall short of covering treatment costs, potentially resulting in financial losses for healthcare providers or increased out-of-pocket expenses for patients. The high cost of hyperthermia treatment can restrict patient access, especially in regions with limited healthcare resources or within healthcare systems that do not fully cover such specialized treatments. This disparity can lead to unequal access to potentially beneficial therapies based on financial considerations rather than medical necessity. Addressing the cost challenge in the hyperthermia cancer treatment market requires a multifaceted approach. This includes leveraging technological innovations to reduce equipment and operational costs, advocating for improved reimbursement policies, generating clinical evidence demonstrating cost-effectiveness, and implementing initiatives to improve affordability and accessibility for patients.
Complexity and Technical Challenges
Hyperthermia treatment involves heating tumors to specific therapeutic temperatures (typically between 40-45°C) while minimizing harm to surrounding healthy tissues. Achieving and maintaining these temperatures is crucial in treating deep-seated tumors like pelvic or abdominal cancers, such as in prostate cancer where precision is necessary to avoid damage to adjacent organs like the bladder or rectum. Engineers designing microwave applicators for hyperthermia must ensure they emit controlled electromagnetic waves that penetrate tissues uniformly. They encounter challenges in delivering sufficient heat to deep tumors without overheating superficial tissues, but advancements like phased array applicators improve heat distribution and treatment effectiveness.
Hyperthermia treatment protocols vary depending on factors such as tumor type, size, and location. For instance, treating cervical cancer might involve combining hyperthermia with radiation therapy. Standardizing protocols across different facilities is difficult due to equipment variability, varying expertise, and patient diversity. Operating hyperthermia equipment requires specialized training in heat transfer principles, thermal dosimetry, and patient care during sessions. Maintaining an adequately trained workforce can be challenging, particularly in smaller healthcare settings with limited training resources.
Key Market Trends
Focus on Combination Therapies
Hyperthermia complements chemotherapy and radiation therapy by increasing the susceptibility of cancer cells to these treatments. Elevated temperatures promote enhanced blood flow to tumors, facilitating improved delivery of chemotherapy drugs and oxygen, thereby boosting treatment efficacy. A preclinical study conducted by researchers at the UCLA Jonsson Comprehensive Cancer Center has suggested that heating solid tumors during CAR T-cell therapy can amplify treatment success. Clinical studies affirm the effectiveness of hyperthermia in combination therapies, prompting ongoing research and adoption by healthcare providers. In their research, scientists found that combining photothermal ablation with CAR T-cell infusion suppressed melanoma tumor growth in mice for up to 20 days, with 33 percent remaining tumor-free thereafter. The study tested mild hyperthermia at approximately 40 degrees Celsius (104 degrees Fahrenheit) to enhance CAR T-cell activity against tumors. Published in Advanced Materials, this research underscores how advances in hyperthermia technology, including improved heating devices and treatment planning systems, facilitate its safe and effective integration into combination therapies.
Magnetic hyperthermia-based cancer therapy (MHCT) has shown therapeutic potential but faces challenges such as low reactive oxygen species (ROS) generation in hypoxic tumor microenvironments and inefficient heat transmission. Dr. Deepika Sharma and her team at the Institute of Nano Science and Technology (INST), Mohali, addressed these issues by developing a vitamin K3-loaded copper zinc ferrite-based magneto thermodynamic treatment. This innovative approach combines magnetic hyperthermia and chemodynamic therapy, leveraging ROS from magneto thermodynamics to induce irreversible oxidative damage to tumor cells, resulting in complete tumor eradication within 30 days. Their findings, published in ACS Applied Materials & Interfaces in 2023, highlight significant advancements in cancer treatment strategies.
In the context of advanced ovarian cancer, chemo-hyperthermia has emerged with promising outcomes. Hyperthermia administered alongside chemotherapy sensitizes cancer cells, enhancing the drugs' effectiveness. Preclinical studies also indicate hyperthermia's potential to stimulate immune cells, augmenting their ability to recognize and attack cancer cells when combined with immune checkpoint inhibitors. This multifaceted approach is currently under investigation in clinical trials across various cancers like melanoma and renal cell carcinoma, driven by the pursuit of improved treatment outcomes, minimized side effects, and innovative cancer management strategies.
Segmental Insights
Device Type Insights
Based on Device Type, the Microwave Hyperthermia Device emerged as the dominating segment in the global market for Hyperthermia Cancer Treatment in 2023.
Application Insights
Based on Application Type, Breast Cancer emerged as the fastest growing segment in the global market for Hyperthermia Cancer Treatment during forecast period. Hyperthermia has demonstrated considerable effectiveness in treating breast cancer when used alongside chemotherapy and radiation therapies. This method allows tumors to be heated precisely while sparing healthy surrounding tissues, thereby minimizing the systemic side effects typically associated with conventional cancer treatments. These benefits significantly enhance the quality of life for breast cancer patients undergoing therapy.
Regional Insights
Based on Region, North America emerged as the dominant region in the Global Hyperthermia Cancer Treatment Market in 2023. This stems from its advanced healthcare infrastructure, robust research capabilities, supportive regulatory environment, high cancer incidence rates, substantial healthcare expenditures, clinical expertise, and strong patient demand. According to the National Cancer Institute (NCI), it is projected that in 2024, approximately 2,001,140 new cancer cases will be diagnosed in the United States, with an estimated 611,720 deaths from the disease. Among men, prostate, lung, and colorectal cancers are anticipated to comprise 48% of new diagnoses, while breast, lung, and colorectal cancers are expected to account for 51% of new diagnoses among women. In 2020, expenditures for cancer care in the United States alone totaled $208.9 billion, with costs expected to rise as the population ages and cancer incidence increases.
Recent Development
- In2024, SourceMark has unveiled an extended collaboration with Gentherm Medical.Leveraging their existing partnership, SourceMark has assumed the role ofsupplier for specific Gentherm patient warming product lines across the UnitedStates. These product lines include Astopad, a resistive warming system forhypothermia prevention and treatment; Norm-O-Temp, a whole-body hyperthermiasystem; Gelli-Roll, a reusable gel pad for warming and cooling; the WarmAirconvective patient warming system; and FilteredFlo patient warming airblankets.
- InJune 2024, New Phase, an Israeli company, received FDA approval to conduct USclinical trials for its patented cancer treatment. The treatment leverages theSarah Nanotechnology System to distinguish and selectively target cancerouscells using thermal energy delivered via nanoparticles. This technology aims totreat metastatic solid tumors by utilizing an alternating magnetic field systemand hyperthermia to specifically eliminate cancer cells while sparing healthytissue.
- In2024, Sona Nanotech Inc. is intensifying clinical trials for its targetedhyperthermia therapy (THT) aimed at treating cancer. Collaborative researchwith the Giacomantonio Immuno-Oncology Research Group at Dalhousie Universityindicates that Sona’s THT, in conjunction with the standard immunotherapyinterleukin-2, not only reduces tumor sizes but also enhances the immunesystem’s responsiveness. Sona Nanotech Inc. has disclosed that a detailedbiomarker analysis of a recent pre-clinical melanoma study conducted atDalhousie University reveals that Sona's THT not only shrinks tumorsindependently but also stimulates the innate immune system to target andeliminate untreated (contralateral) tumors when combined with a standardimmunotherapeutic drug.
Key Market Players
- Pyrexar Medical
- MagForce AG
- Hydrosun Medizintechnik GmbH
- Andromedic Srl
- YAMAMOTO VINITA CO., LTD
- OncoTherm Kft.
- Nanoprobes, Inc.
- Chongqing Haifu Medical Technology Co.,Ltd.
- Novavida Integrative Medical Center
- InnoMedicus Ltd.
| By Device Type | By Application | By End User | By Region |
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy